It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Around 40% of preterm births are attributed to ascending intrauterine infection, and Ureaplasma parvum (UP) is commonly isolated in these cases. Here we present a mouse model of ascending UP infection that resembles human disease, using vaginal inoculation combined with mild cervical injury induced by a common spermicide (Nonoxynol-9, as a surrogate for any mechanism of cervical epithelial damage). We measure bacterial load in a non-invasive manner using a luciferase-expressing UP strain, and post-mortem by qPCR and bacterial titration. Cervical exposure to Nonoxynol-9, 24 h pre-inoculation, facilitates intrauterine UP infection, upregulates pro-inflammatory cytokines, and increases preterm birth rates from 13 to 28%. Our results highlight the crucial role of the cervical epithelium as a barrier against ascending infection. In addition, we expect the mouse model will facilitate further research on the potential links between UP infection and preterm birth.
Ureaplasma parvum is often isolated from intrauterine infections, which are associated with 40% of preterm births. Here, Pavlidis et al. present a mouse model of ascending U. parvum infection that resembles human disease, and show that mild cervical damage promotes intrauterine infection, inflammation and preterm birth.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Edinburgh, Tommy’s Centre for Maternal and Fetal Health at the MRC Centre for Reproductive Health, Queen’s Medical Research Institute, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
2 Cardiff University, Division of Infection and Immunity, School of Medicine, Cardiff, UK (GRID:grid.5600.3) (ISNI:0000 0001 0807 5670)
3 University of Edinburgh, MRC Centre for Inflammation Research, Queen’s Medical Research Institute, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 University of Bristol, Faculty of Health Sciences, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)
5 University of Edinburgh, Tommy’s Centre for Maternal and Fetal Health at the MRC Centre for Reproductive Health, Queen’s Medical Research Institute, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) ; NINE Edinburgh BioQuarter, Usher Institute, University of Edinburgh, Edinburgh, UK (GRID:grid.4305.2)